J C Gallagher1, D Goldgar. 1. Bone Metabolism Unit, Creighton University Medical Center, Omaha, NE 68131.
Abstract
OBJECTIVE: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. DESIGN: Two-year, double-blind, randomized clinical trial. SETTING:University medical center. PATIENTS: Fifty postmenopausal women with vertebral fractures recruited by referral. INTERVENTION: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium less than 2.74 mmol/L (less than 11.0 mg/dL) or urine calcium less than 9.96 mmol/d (less than 400 mg/d). MEASUREMENTS AND MAIN RESULTS: After 2 years, the mean dose of calcitriol in the treated group was 0.62 micrograms/d. Bone mineral density of the spine increased 1.94% with calcitriol therapy and decreased 3.92% with placebo (P = 0.001). Total body calcium increased 0.21% with calcitriol therapy and decreased 1.85% with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. CONCLUSION: The treatment of postmenopausal osteoporotic women withsynthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy.
RCT Entities:
OBJECTIVE: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. DESIGN: Two-year, double-blind, randomized clinical trial. SETTING: University medical center. PATIENTS: Fifty postmenopausal women with vertebral fractures recruited by referral. INTERVENTION: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium less than 2.74 mmol/L (less than 11.0 mg/dL) or urine calcium less than 9.96 mmol/d (less than 400 mg/d). MEASUREMENTS AND MAIN RESULTS: After 2 years, the mean dose of calcitriol in the treated group was 0.62 micrograms/d. Bone mineral density of the spine increased 1.94% with calcitriol therapy and decreased 3.92% with placebo (P = 0.001). Total body calcium increased 0.21% with calcitriol therapy and decreased 1.85% with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. CONCLUSION: The treatment of postmenopausal osteoporoticwomen with synthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy.
Authors: R Nuti; G Bianchi; M L Brandi; R Caudarella; E D'Erasmo; C Fiore; G C Isaia; G Luisetto; M Muratore; P Oriente; S Ortolani Journal: Rheumatol Int Date: 2005-11-10 Impact factor: 2.631
Authors: S Strugnell; V Byford; H L Makin; R M Moriarty; R Gilardi; L W LeVan; J C Knutson; C W Bishop; G Jones Journal: Biochem J Date: 1995-08-15 Impact factor: 3.857
Authors: L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow Journal: Osteoporos Int Date: 2009-12-04 Impact factor: 4.507
Authors: S A Brown; D A Ontjes; G E Lester; R K Lark; M B Hensler; A D Blackwood; M J Caminiti; D C Backlund; R M Aris Journal: Osteoporos Int Date: 2003-05-28 Impact factor: 4.507